"Cytosine Arabinoside with
Daunorubicin or Adriamycin for Therapy of Acute Myelocytic Leukemia: A CALGB Study." Blood 60 (2): 454-62.
Caption: Figure 7: Effect of EGFR inhibition with canertinib treatment on the sensitivity of MCF-7 and MCF-7(TamR) cells to a 48-hour treatment with (a) paclitaxel and (b)
daunorubicin. Cells were subjected to a 48-hour cytotoxic treatment with the addition of (red) 0 [micro]M, (blue) 0.1 [micro]M, or (green) 1 [micro]M canertinib before 4 days recovery in the same medium minus the cytotoxic.
JQ1 Synergises with
Daunorubicin in Inducing AML Cell Death.
Designed with Jazz's CombiPlex technology, Vyxeos is a unique liposomal formulation that delivers a fixed-ratio of
daunorubicin and cytarabine to the bone marrow that has been shown to have synergistic effects at killing leukemia cells in vitro and in animal models.
Oszczapowicz, "A comparison of the stability of doxorubicin and
daunorubicin in solid state," Journal of Pharmaceutical and Biomedical Analysis, vol.
In our preliminary data, compounds 1-4 were evaluated for their potential selective antiproliferative activity against parental gastric (EPG85- 257) and pancreatic (EPP-181) human cancer cells and their drug-resistant counterparts, selected against mitoxantrone (RNOV) or
daunorubicin (RDB), respectively, using a proliferation assay (Reis et al., 2015).
Celator's lead product is VYXEOS (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:
daunorubicin that has completed a Phase 3 trial for the treatment of acute myeloid leukemia.
Daunorubicin is an anticancer drug with high side effects, including bone marrow repression and heart toxicity, which is widely used for the treatment of ALL.
The combination of gold -- aptamer nanoparticles has been used in this research to carry
daunorubicin drug into the target tissue.
Other treatments include local destruction (cryotherapy), topical alitretinoin (9-cis-retinoic acid), intralesional interferon or vinblastine, superficial radiotherapy, liposomal doxorubicin,
daunorubicin, or paclitaxel.
It has been most commonly reported after intravenous use of chemotherapeutic agents such as 5-fluorouracil, docetaxel and combinations of methotrexate, cytosine arabinoside,
daunorubicin, 6-mercaptopurine, cyclophosphamide, doxorubicin, bleomycin, vinka alkaloids and dacarbazine.